Epizyme
IPO
Transformative therapies against novel epigenetic targets
- Headquarters
- Cambridge, Massachusetts
- Employees
- 201–500
- Founded
- 2007
- Business Model
- B2B
- Website
- epizyme.com
- Total Funding
- $154.0M
- Last Round
- $100.0M Growth EquityNov 2019
About
Epizyme is a commercial-stage biopharmaceutical company creating innovative drugs for major diseases based on epigenetics discoveries. It developed therapies targeting epigenetic targets for cancer and was acquired by Ipsen.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account